INO has been one of the real poster-boys for the so-called Robinhood bubble. The company is a chronic underperformer in the biotech space with a likely failed vaccine candidate -- given its lack of detail in any update -- powering the action despite the fact that vaccines generally aren't profitable in the first place, and this isn't going to be it. Caution!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.